Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Stock Information for Citius Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.